NTRK1 and Miyoshi myopathy: Although oncogenic activating mutations in crucial regulators of growth and survival signaling, such as receptor tyrosine kinases (RTKs), rarely occur in MM, these kinases and downstream pathways are frequently overexpressed and hyperactivated in this cancer [11,13,14,24].